Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Head and Neck Cancer: early-phase trial registry
89 of 260 indexed Head and Neck Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #39 of 28,707 conditions by registered trial count.
260 US clinical trials · 89 currently recruiting · #39 of 28,707 conditions by registered trial count
Head and Neck Cancer: 260 US clinical trials tracked, 89 recruiting.
Head and Neck Cancer is the subject of 260 registered US clinical trials on ClinicalTrials.gov, 89 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 137 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 19 of these trials.
Enrollment posture brief
Registry condition head-and-neck-cancer
OPEN 89 | RECR 34% | LATE 13 | EARLY 137 | RANK #39 | SPON 19
Volume-matched condition peers
Nearest open-share peer: Recurrent Malignant Solid Neoplasm (34% recruiting · 38 trials)
Head and Neck Cancer lists 89 open slots (34% of 260 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Head and Neck Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Head and Neck Cancer is recruiting below its size-band peers.
89 of 260 indexed trials (34.2%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Head and Neck Cancer trials is spread across many organizations.
M.D. Anderson Cancer Center accounts for 19 of 260 trials (7.3%). 124 distinct sponsors appear on at least one study for this condition label.
-
Most Head and Neck Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 53 among the 251 trials that report a genuine target (sentinel values excluded). 165 of those (65.7%) plan for fewer than 100 participants.
-
Head and Neck Cancer research is mostly interventional.
213 interventional and 47 observational studies make up this index (81.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
260 total, page 4 of 6
Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)
Medical College of Wisconsin
NCT05538533
Imaging With a PET Agent for Detection of Cancers of the Head and Neck
Memorial Sloan Kettering Cancer Center
NCT03631017
ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck Cancer
Rakuten Medical
NCT05182866
Trial of Ibrutinib Combined With Nivolumab or Cetuximab to Treat Recurrent/Metastatic HNSCC
University of California, San Diego
NCT03646461
A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT06145412
Creation of the BioBank, Early Detection and Discovery Biomarkers
Corewell Health East
NCT00901680
PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine
Labcorp Corporation of America Holdings
NCT05697198
Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study
Stanford University
NCT03245788
Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer
Radiation Therapy Oncology Group
NCT01302834
Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
NCT00047008
Blood Proteins in Predicting Treatment Benefit in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Vanderbilt-Ingram Cancer Center
NCT00896675
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
Five Prime Therapeutics
NCT02526017
Sexual Behavior in Oropharyngeal Patients Versus Head and Neck Cancer Patients, With or Without HPV Infection
M.D. Anderson Cancer Center
NCT00508170
Enhanced Care Coordination for Head and Neck Cancer Survivors
University of Pittsburgh
NCT04813172
Reliability and Validity of Patient Reported Outcome Measures in Head and Neck Cancer
Mayo Clinic
NCT02554968
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
Dana-Farber Cancer Institute
NCT00095875
Fruit and Vegetable Extracts in Treating Patients With Stage I-IV, Stage IVA/IVB Head and Neck Cancer
Wake Forest University Health Sciences
NCT00064298
Perioperative Gabapentin Use In Head And Neck Mucosal Surgery Patients
Washington University School of Medicine
NCT02926573
A Study of MEHD7945A Versus Cetuximab in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of The Head And Neck
Genentech
NCT01577173
Use of a Non-ICU Specialty Ward For Immediate Post-operative Management of Head and Neck Free Flaps
University of California, Davis
NCT03340038
Docetaxel in Treating Patients With Solid Tumors
Alliance for Clinical Trials in Oncology
NCT00003565
Optimization of Smoking Cessation Strategies Concurrent With Treatment of Tobacco Related Malignancies
University of Kentucky
NCT02048917
Pharmacogenomic Study in Patients of Lung, Colorectal and Head/Neck Cancers Receiving Chemotherapy
University of Kansas Medical Center
NCT00442520
Trial of Induction Chemotherapy With Carboplatin and Paclitaxel, Followed by Concurrent Chemotherapy/Radiation Therapy With ZD1839 (IRESSA), 5-FU, Hydroxyurea, and Twice-Daily Radiation, Followed by Adjuvant ZD1839 Monotherapy in Patients With Locally Advanced Head & Neck Cancer
University of Chicago
NCT01185171
Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection
GE Healthcare
NCT00918281
Chemotherapy and Radiation Therapy Following Surgery in Treating Patients With Head and Neck Cancer
Radiation Therapy Oncology Group
NCT00011999
Validity and Reliability of Outcome Measures in Patients With Cancer of the Head and Neck
Mayo Clinic
NCT01952821
Feasibility Study of the Head and Neck Survivorship Tool: Assessment and Recommendations (HN-STAR)
Memorial Sloan Kettering Cancer Center
NCT02571673
Adaptive Radiotherapy for Head and Neck Cancer
Memorial Sloan Kettering Cancer Center
NCT03096808
Cisplatin and Radiation Therapy in Treating Patients With Stage IV Cancer of the Head and Neck
Radiation Therapy Oncology Group
NCT00002932
2 Phase Use Of Educational Materials In Head And Neck Cancer Center
Massachusetts General Hospital
NCT02204631
Nutrition and Resistance Training in Head and Neck Cancer
Vanderbilt University
NCT00696553
Pembrolizumab in Combination With CRT for LA-SCCHN
Sanford Health
NCT02586207
Study of Chemotherapy With Cisplatin/Carboplatin, and Docetaxel With or Without Erlotinib in Patients With Head and Neck Squamous Cell Carcinomas Amenable for Surgical Resection
M.D. Anderson Cancer Center
NCT01927744
Low-Cost, Portable Flexible Nasopharyngoscope in Head & Neck Cancers in Low Resource Settings - Optimization Phase
Duke University
NCT04905134
A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer
TyrNovo
NCT04474470
Imaging Study on Halcyon 4.0 System for Patients Receiving Radiation Therapy
Washington University School of Medicine
NCT05427214
Cross-Sectional Study of Oral Health in Patients After Parotid-Sparing Radiation Therapy for Head and Neck Cancer
University of Michigan Rogel Cancer Center
NCT01663246
Carboplatin, Capecitabine, and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer
University of Virginia
NCT00114153
Dentures and Dental Implants in Treating Patients Undergoing Surgery for Mouth Cancer
Jonsson Comprehensive Cancer Center
NCT00006341
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
PureTech
NCT04666688
Study of the CD40 Agonistic Monoclonal Antibody APX005M
Apexigen America
NCT02482168
Multimodality Risk Adapted Tx Including Induction Chemo for SCCHN Amenable to Transoral Surgery
UNC Lineberger Comprehensive Cancer Center
NCT01612351
Functional Sparing of Salivary Glands Using MRI Sialography for Patients Undergoing Definitive Radiation Therapy for Head and Neck Cancers of the Oropharynx
UNC Lineberger Comprehensive Cancer Center
NCT03418792
L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors
Memorial Sloan Kettering Cancer Center
NCT00003430
Biopsy of Human Tumors for Cancer Stem Cell Characterization: a Feasibility Study
Stanford University
NCT00610415
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
NCT00437372
A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors
Jacobio Pharmaceuticals Co.
NCT03518554
Zileuton in Preventing Lung Cancer in Patients With Bronchial Dysplasia
Barbara Ann Karmanos Cancer Institute
NCT00056004
Paclitaxel and Radiation Therapy Plus Chemoprotection With Amifostine in Treating Patients With Stage III or Stage IV Head and Neck Cancer
Massachusetts General Hospital
NCT00003193
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 63 |
| Phase 2 | 74 |
| Phase 3 | 11 |
| Phase 4 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Head and Neck Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Head and Neck Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Head and Neck Cancer page
260 registered trials, 89 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 89 Head and Neck Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Head and Neck Cancer trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Head and Neck Cancer condition card totals 260 registered trials; most-linked intervention cisplatin; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.